Shefali AGARWAL, MD
Before joining Onxeo, Dr. Shefali Agarwal was Chief Medical Officer at Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies for cancer and other serious diseases, where she leads the global clinical development and regulatory strategy for tazemetostat for the treatment of cancer. Prior to joining Epizyme in 2018, Dr. Agarwal held leadership positions across medical research, clinical development, clinical operations and medical affairs. She most recently served as chief medical officer at SQZ Biotech, where she built and led the clinical development organization, which included clinical research operations and the regulatory function. Before SQZ Biotech, Dr. Agarwal also held leadership positions at Curis and Tesaro. At Curis, she oversaw the Phase 2 study for its dual HDAC/PI3K inhibitor in diffuse large B-cell lymphoma, and the Phase 1 study in solid tumors for its oral checkpoint inhibitor. At Tesaro, she led the NDA and EMA submissions for ZEJULA(r) (niraparib) in ovarian cancer. Dr. Agarwal has also held positions of increasing responsibility at Covidien, AVEO Oncology and Pfizer. In addition to receiving her medical degree, Dr. Agarwal holds a master’s of public health and a master’s of science in business.
Shefali AGARWAL, MDPRESIDENT AND CHIEF EXECUTIVE OFFICER
He began his career as Deputy Chief Financial Officer at Total in Cameroon in 1990 and then as Financial Auditor at Ernst & Young on various missions in the industrial and financial sectors.
He then moved to the pharmaceutical industry where, from 1996 to 2006, he held positions of increasing responsibility within the finance division of Pfizer France: first in charge of the treasury and internal audit as Director of Treasury, Tax and Audit. In this position, he was responsible in particular for financial risk management for the French subsidiaries of Pfizer and he managed the financial implementation of various restructuring operations (including two mergers, one with Warner-Lambert in 2000 and then Pharmacia in 2003) as well as the implementation of tax and financial optimisation schemes.
Nicolas Fellmann is a graduate of Lyon Graduate School of Management (EM Lyon).
Nicolas FELLMANNCHIEF FINANCIAL OFFICER
Audrey Legentil-Duméry worked as a Senior HR consultant with a Paris-based agency, managing HR on behalf of diverse companies, notably accompanying SME’s through periods of growth and transition.
Ms. Legentil-Duméry successfully conducted several missions in the pharma and biotech sectors.
Audrey Legentil-Duméry holds a Magister and a Master in Management and Intercultural Communication from CELSA (Sorbonne, Paris).
Audrey LEGENTIL-DUMERYDIRECTOR OF HUMAN RESOURCES
Huiping Jiang began her career as Director of Regulatory Affairs at Boehringer Ingelheim in 2013 and then as Vice President of Regulatory Affairs at Epizyme in Cambridge, MA starting in 2019. While at Epizyme, she then became Senior Vice President and Head of Regulatory Affairs until 2021. During her time at Epizyme, she was responsible for leading the regulatory strategies, submissions and approvals for the drugs Tazverik and Cyltezo. Finally, prior to joining Onxeo, she served as Interim President at Qx Therapeutics from 2021.
Huiping Jiang has a Ph.D. in cell and molecular biology from Clarkson University and then participated in a post-doctoral research program on genetic engineering and molecular genetics in signal transduction
Huiping JIANGSENIOR VICE-PRESIDENT REGULATORY AFFAIRS AND QUALITY ASSURANCE
Ashish Gulati has more than 20 years of experience in the healthcare field: after a career in research at the All India Institute of Medical Sciences in New Delhi in 2000, he joined Roche as a Medical Manager in Oncology and Rheumatology. After 8 years at Roche, he joined AstraZeneca as Senior Global Medical Officer in Gaithersburg. He then joined Abbvie in 2018 as Medical Director specialized in Myeloid & MM and finally Takeda Oncology in 2020 as Global Medical Leader, specialized in lung cancer. During his career, he participated in the global launch for key molecules in Solid Tumor and Hematological Malignancies: (Venetoclax for AML, Mobocertinib for exon 20 ins NSCLC, Avastin for GBM, mRCC, Nanoxel for MBC, Benralizumab for SA, Tocilizumab for RA)
Ashish Gulati first obtained a doctorate in medicine at the University of Aarhus. He then went on to Berkeley, Harvard and King's College to study leukemia, particularly Myeloid Malignancies. As previously mentioned, he was also a resident at the All India Institute of Medical Sciences in New Delhi.